Huang Hai-Li, Wu Ben-Yan, Zhu Xu-Dong, You Wei-Di, Wang Wei-Hua, Wang Meng-Wei
Department of Geriatric Gastroenterology, General Hospital of PLA, Beijing 100853, China.
Zhonghua Zhong Liu Za Zhi. 2008 Jul;30(7):506-10.
Some members of the S100 gene family have been suggested to be associated with cancer development and metastasis. Our previous cDNA micro-array studies have showed S100A6 expression is elevated in gastric cancer compared with that in paired normal mucosa. To validate our previous results and further investigate the possible role of S100A6 gene in gastric cancer, we carried out this detailed S100A6 expression analysis in more matched gastric cancer samples.
S100A6 expression was detected in 20 paired fresh surgical samples of gastric tumor tissue and matched non-cancerous mucosa by QRT-PCR. A gastric cancer tissue microarray (TMA) containing 1020 duplicate matched normal mucosa, gastric cancer tissue and metastatic lymph node tissue cores from 208 gastric cancer patients was constructed. S100A6 expression was detected by immunohistochemistry and the correlation between S100A6 expression with clinicopathological factors and survival was analyzed.
As quantitated by QRT-PCR, S100A6 transcript level was elevated in 73.7% of the primary cancer lesions with an average 2.25-fold up-regulation than that in matched non-neoplastic mucosa. As displayed by immunohistochemistry, the positive rate of S100A6 in non-neoplastic mucosa, tumor lesions and metastatic lymph nodes was 34.3%, 84.1% and 90.9%, respectively. S100A6 expression level in cancer and metastatic lymph node was significantly higher than their matched non-neoplastic mucosa (P < 0.05). 65.5% of patients showed an increased S100A6 expression in cancer tissue compared with that in matched normal mucosa. S100A6 overexpression was associated with larger tumor size and deeper invasion (P = 0.022 and P = 0.009). No evidence was found for an association between S100A6 expression level and other variables, including tumor grade, nodal metastases, and TNM stage. There was no association between S100A6 expression level and survival. But compared with paired non-neoplastic mucosa, an increased S100A6 expression in tumor lesion predicated a decreasing suvival if compared with a decreased S100A6 expression, though the difference was statistically not significant.
Elevated expression of S100A6 gene may be an early event in the development and progression of gastric cancer. Further study of this gene may be helpful for understanding the nature of gastric carcinoma.
有研究表明,S100基因家族的一些成员与癌症的发生和转移有关。我们之前的cDNA微阵列研究显示,与配对的正常黏膜相比,胃癌中S100A6的表达升高。为了验证我们之前的结果,并进一步研究S100A6基因在胃癌中的可能作用,我们对更多配对的胃癌样本进行了详细的S100A6表达分析。
通过实时定量聚合酶链反应(QRT-PCR)检测20对新鲜手术切除的胃癌组织样本及其配对的癌旁正常黏膜中S100A6的表达。构建了一个包含208例胃癌患者的1020个重复配对的正常黏膜、胃癌组织和转移淋巴结组织芯的胃癌组织芯片(TMA)。采用免疫组织化学法检测S100A6的表达,并分析S100A6表达与临床病理因素及生存的相关性。
通过QRT-PCR定量分析,73.7%的原发性癌灶中S100A6转录水平升高,平均上调2.25倍,高于配对的非肿瘤性黏膜。免疫组织化学结果显示,S100A6在非肿瘤性黏膜、肿瘤病灶和转移淋巴结中的阳性率分别为34.3%、84.1%和90.9%。癌组织和转移淋巴结中S100A6的表达水平显著高于其配对的非肿瘤性黏膜(P<0.05)。65.5%的患者癌组织中S100A6的表达高于配对的正常黏膜。S100A6过表达与肿瘤体积较大和浸润较深有关(P = 0.022和P = 0.009)。未发现S100A6表达水平与其他变量之间存在关联,包括肿瘤分级、淋巴结转移和TNM分期。S100A6表达水平与生存无关联。但与配对的非肿瘤性黏膜相比,肿瘤病灶中S100A6表达增加的患者与S100A6表达降低的患者相比,生存率有下降趋势,尽管差异无统计学意义。
S100A6基因表达升高可能是胃癌发生和发展的早期事件。对该基因的进一步研究可能有助于理解胃癌的本质。